Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Nishijima, Takeshi ^a,b   Gatanaga, Hiroyuki ^a,b   Shimbo, Takuro ^a   Komatsu, Hirokazu ^c   Endo, Tomoyuki ^d   Horiba, Masahide ^e   Koga, Michiko ^f   Naito, Toshio ^g   Itoda, Ichiro ^h   Tei, Masanori ^c   Fujii, Teruhisa ⁱ   Takada, Kiyonori ^j   Yamamoto, Masahiro ^k   Miyakawa, Toshikazu ^b   Tanabe, Yoshinari ^l   Mitsuya, Hiroaki ^b,m   Oka, Shinichi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e Higashisaitama National Hospital   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Shirakaba Clinic   (Japan)

ⁱ HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^j EHIME UNIVERSITY HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^l NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^m NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LOPINAVIR; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PYRROLIDINONES; SULFONAMIDES; VIRAL LOAD;

EID: 84881340308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073639     Document Type: Article

References (46)

1. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260. doi:10.1056/NEJMoa051871. PubMed: 16421366.
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201. doi:10.1001/jama.292.2.191. PubMed: 15249568.
3. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, et al. (2005) Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20: 743-746. doi:10.1093/ndt/gfh658. PubMed: 15741212.
4. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281. doi:10.1097/QAD.0b013e3280b07b33. PubMed: 17545703.
5. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, et al. (2008) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47: 74-78. doi:10.1097/QAI.0b013e31815acab8. PubMed: 17971715.
6. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, et al. (2010) Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 55: 49-57. doi:10.1097/QAI.0b013e3181f9c0f7. PubMed: 20431394.
7. Kinai E, Hanabusa H, (2009) Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 25: 387-394. doi:10.1089/aid.2008.0202. PubMed: 19361280.
8. Winston A, Amin J, Mallon P, Marriott D, Carr A, et al. (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7: 105-111. doi:10.1111/j.1468-1293.2006.00349.x. PubMed: 16420255.
9. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, et al. (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22: 2155-2163. doi:10.1097/QAD.0b013e3283112b8e. PubMed: 18832879.
10. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, et al. (2007) Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 1165-1173. PubMed: 18240857.
11. Nolan D, Mallal S, (2004) Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 9: 849-863. PubMed: 15651744.
12. Lewis W, Day BJ, Copeland WC, (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2: 812-822. doi:10.1038/nrd1201. PubMed: 14526384.
13. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, et al. (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89: 513-519. doi:10.1038/labinvest.2009.14. PubMed: 19274046.
14. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, et al. (2010) Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78: 1171-1177. doi:10.1038/ki.2010.318. PubMed: 20811330.
15. Peyrière H, Reynes J, Rouanet I, Daniel N, de Boever CM, et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269-273. doi:10.1097/00126334-200403010-00007. PubMed: 15076241.
16. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791-1801. doi:10.1093/infdis/jir188. PubMed: 21606537.
17. Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, et al. (2008) Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 13: 1077-1082. PubMed: 19195333.
18. Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, et al. (2012) Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLOS ONE 7: e29977. doi:10.1371/journal.pone.0029977. PubMed: 22242194.
19. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505. doi:10.1086/655681. PubMed: 20673002.
20. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, et al. (2008) The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83: 265-272. doi:10.1038/sj.clpt.6100269. PubMed: 17597712.
21. Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197: 102-108. doi:10.1086/524061. PubMed: 18171292.
22. Tressler R, Godfrey C, (2012) NRTI backbone in HIV treatment: will it remain relevant? Drugs 72: 2051-2062. doi:10.2165/11640830-000000000-00000. PubMed: 23083109.
23. Moyle G, (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22: 911-936; discussion 898 doi:10.1016/S0149-2918(00)80064-8. PubMed: 10972629.
24. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, et al. (2012) Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26: 867-875. doi:10.1097/QAD.0b013e328351f68f. PubMed: 22313955.
25. Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, et al. (2012) High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res 96: 65-69. doi:10.1016/j.antiviral.2012.07.009. PubMed: 22892171.
26. Wever K, van Agtmael MA, Carr A, (2010) Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55: 78-81. doi:10.1097/QAI.0b013e3181d05579. PubMed: 20173649.
27. Taiwo B, Swindells S, Berzins B, et al. Week 48 results of the Maraviroc Plus Darunavir/ritonavir Study (MIDAS) for treatment-naive patients infected with R5-tropic HIV-1 [abstract TUPE099]. Presented at: 19th International AIDS Conference;(2012); Washington DC, USA.
28. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, et al. (2012) A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials 13: 119-130. doi:10.1310/hct1303-119. PubMed: 22592092.
29. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, et al. (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369: 1169-1178. doi:10.1016/S0140-6736(07)60497-8. PubMed: 17416261.
30. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, et al. (2007) Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370: 49-58. doi:10.1016/S0140-6736(07)61049-6. PubMed: 17617272.
31. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al. (2011) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25: 2113-2122. doi:10.1097/QAD.0b013e32834bbaa9. PubMed: 21857490.
32. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, et al. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322: 1098-1105. doi:10.1056/NEJM199004193221602. PubMed: 2320079.
33. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, et al. (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340: c869. doi:10.1136/bmj.c869. PubMed: 20332511.
34. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, et al. (2011) Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS ONE 6: e22661. doi:10.1371/journal.pone.0022661. PubMed: 21799928.
35. Cockcroft DW, Gault MH, (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41. doi:10.1159/000180580. PubMed: 1244564.
36. Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, et al. (2009) Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-e116. doi:10.1086/598507. PubMed: 19400747.
37. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992. doi:10.1053/j.ajkd.2008.12.034. PubMed: 19339088.
38. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, (2010) Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56: 32-38. doi:10.1053/S0272-6386(10)01197-2. PubMed: 20416999.
39. Bredeek UF, Guadron R, Yolo R, et al. (2012) A Switch From TDF/FTC To Raltegravir In Patients On A Boosted Protease Inhibitor Is Effective In Reducing Proteinuria And Increasing GFR [abstract: H1-1399b]. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12. USA: San Francisco.
40. Gallant JE, Moore RD, (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23: 1971-1975. doi:10.1097/QAD.0b013e32832c96e9. PubMed: 19696652.
41. Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, et al. (2006) Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22: 744-748. doi:10.1089/aid.2006.22.744. PubMed: 16910829.
42. Nishijima T, Shimbo T, Komatsu H, Takano M, Tanuma J, et al. (2013) Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother. PubMed: 23467792.
43. Dauchy FA, Lawson-Ayayi S, de la Faille R, Bonnet F, Rigothier C, et al. (2011) Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 80: 302-309. doi:10.1038/ki.2011.124. PubMed: 21544066.
44. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, et al. (2010) Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers. Clin Infect Dis 51: 937-946. doi:10.1086/656412. PubMed: 20839968.
45. Kudo K, Konta T, Mashima Y, Ichikawa K, Takasaki S, et al. (2011) The association between renal tubular damage and rapid renal deterioration in the Japanese population: the Takahata study. Clin Exp Nephrol 15: 235-241. doi:10.1007/s10157-010-0392-y. PubMed: 21225309.
46. Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, et al. (2012) A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses 28: 1196-1206. doi:10.1089/aid.2011.0336. PubMed: 22364141.